Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 14/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 14/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 14/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 14/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 14/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 14/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 14/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 14/20 | 1.00 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | ASPH | Q12797 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27358258 | 0.85 | HDAC3 (0.73) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL20226797 | 0.82 | HDAC4 (0.70) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL20214211 | 0.82 | HDAC3 (0.70) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL20214210 | 0.82 | HDAC3 (0.70) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL20226796 | 0.76 | HDAC3 (0.61) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL19862461 | 0.76 | HDAC1 (0.74) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL20214549 | 0.73 | HDAC3 (0.57) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL22018078 | 0.73 | HDAC1 (0.72) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL13029037 | 0.72 | HDAC1 (0.79) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| Belinostat SCHEMBL29712104 | 0.71 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046715-B2 | Boronic derivatives of hydroxamates as anticancer agents | XAVIER UNIVERSITY OF LOUISIANA (US) | 2021-06-29 | — | — | US | claimed |
| US-20200181175-A1 | BORONIC DERIVATIVES OF HYDROXAMATES AS ANTICANCER AGENTS | XAVIER UNIVERSITY OF LOUISIANA | 2020-06-11 | — | — | US | claimed |
| WO-2018102261-A2 | BORONIC DERIVATIVES HYDROXAMATES AS ANTICANCER AGENTS | XAVIER UNIVERSITY OF LOUISIANA (US) | 2018-06-07 | — | — | WO | claimed |
| US-11046715-B2 | Boronic derivatives of hydroxamates as anticancer agents | XAVIER UNIVERSITY OF LOUISIANA (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200181175-A1 | BORONIC DERIVATIVES OF HYDROXAMATES AS ANTICANCER AGENTS | XAVIER UNIVERSITY OF LOUISIANA | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181175-A1 | BORONIC DERIVATIVES OF HYDROXAMATES AS ANTICANCER AGENTS | BCOR, BRDT, HDAC1 | HDAC1 3/4885HDAC8 6/4885HDAC3 22/4885 |
| US-11046715-B2 | Boronic derivatives of hydroxamates as anticancer agents | BCOR, BRDT, HDAC1 | HDAC1 3/4885HDAC8 6/4885HDAC3 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.